Share：
Share this content in WeChat
X
[Chinese] [PDF] 28 1
• Review •
Research status and progress in pre-treatment evaluation for parametrial invasion of cervical cancer
CHEN Jiejie  ZHANG Yuejie  YANG Zihan  FAN Rongke  JIANG Wenliang  LIU Jinjin  DONG Linxiao  WU Qingxia  WANG Meiyun 

Cite this article as CHEN J J, ZHANG Y J, YANG Z H, et al. Research status and progress in pre-treatment evaluation for parametrial invasion of cervical cancer[J]. Chin J Magn Reson Imaging, 2026, 17(6): 222-228. DOI:10.12015/issn.1674-8034.2026.06.028.


[Abstract] Cervical cancer is the fourth most common malignant neoplasm among women worldwide, and it seriously threatens women's health. Parametrial invasion (PMI) is a critical adverse prognostic factor in cervical cancer, and its presence directly impacts the patient's clinical staging and treatment decisions. Therefore, accurate evaluation of PMI is of great significance for formulating individualized treatment strategies and improving patient prognosis. In current clinical practice, the conventional pre-treatment evaluation methods for PMI primarily include clinical examination and imaging examination. In terms of clinical examination, conventional palpation is simple but has limited accuracy, whereas examination under anesthesia (EUA) and augmented EUA (aEUA) can significantly improve diagnostic precision. In radiological evaluation, ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) each possess distinct advantages and limitations, with MRI serving as the primary diagnostic modality. Furthermore, emerging technologies such as multimodal imaging and medical imaging artificial intelligence technologies offer novel approaches to enhance the diagnostic accuracy of PMI in cervical cancer. This article systematically reviews the current research status, advancements, and limitations regarding the clinical and imaging evaluation of PMI in cervical cancer, aiming to provide a more comprehensive reference for precise clinical staging and treatment decision-making, while also offering guidance for future research directions.
[Keywords] cervical cancer；parametrial invasion；clinical examination；ultrasound；computed tomography；magnetic resonance imaging

CHEN Jiejie1   ZHANG Yuejie2   YANG Zihan1   FAN Rongke2   JIANG Wenliang2   LIU Jinjin1   DONG Linxiao2   WU Qingxia1, 2*   WANG Meiyun1, 2, 3  

1 Department of Medical Imaging, People's Hospital of Zhengzhou University (Henan Provincial People's Hospital), Zhengzhou, 450003, China

2 Department of Medical Imaging, People's Hospital of Henan University (Henan Provincial People's Hospital), Zhengzhou, 450003, China

3 Institution of Biomedical Research, Henan Academy of Sciences, Zhengzhou, 450046, China

Corresponding author: WU Q X, E-mail: qxwu@zzu.edu.cn

Conflicts of interest   None.

Received  2026-01-09
Accepted  2026-05-30
DOI: 10.12015/issn.1674-8034.2026.06.028
Cite this article as CHEN J J, ZHANG Y J, YANG Z H, et al. Research status and progress in pre-treatment evaluation for parametrial invasion of cervical cancer[J]. Chin J Magn Reson Imaging, 2026, 17(6): 222-228. DOI:10.12015/issn.1674-8034.2026.06.028.

[1]
PIMPLE S, MISHRA G. Cancer cervix: Epidemiology and disease burden[J/OL]. Cytojournal, 2022, 19: 21 [2026-01-08]. https://pubmed.ncbi.nlm.nih.gov/35510109/. DOI: 10.25259/CMAS_03_02_2021.
[2]
BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
[3]
XIE L Q. Application of transvaginal ultrasonography in the diagnosis of parametrial invasion in cervical cancer[J]. Oncoradiology, 2021, 30(5): 410-413. DOI: 10.19732/j.cnki.2096-6210.2021.05.015.
[4]
SALIB M Y, RUSSELL J H B, STEWART V R, et al. 2018 FIGO staging classification for cervical cancer: added benefits of imaging[J]. RadioGraphics, 2020, 40(6): 1807-1822. DOI: 10.1148/rg.2020200013.
[5]
ZHANG Y, ZOU J, LI L R, et al. Comprehensive assessment of postoperative recurrence and survival in patients with cervical cancer[J/OL]. Eur J Surg Oncol, 2024, 50(10): 108583 [2026-01-08]. https://pubmed.ncbi.nlm.nih.gov/39116515/. DOI: 10.1016/j.ejso.2024.108583.
[6]
BARQUET-MUÑOZ S, BANDALA-JAQUES A, PEREZ-MONTIEL M D, et al. Factors associated with parametrial involvement in endometrial carcinoma in patients treated with radical hysterectomy[J]. Int J Surg Pathol, 2024, 32(7): 1241-1247. DOI: 10.1177/10668969231225773.
[7]
ABU-RUSTUM N R, YASHAR C M, AREND R, et al. NCCN guidelines® insights: cervical cancer, version 1.2024: featured updates to the NCCN guidelines[J]. J Natl Compr Cancer Netw, 2023, 21(12): 1224-1233. DOI: 10.6004/jnccn.2023.0062.
[8]
SODEIKAT P, LIA M, MARTIN M, et al. The importance of clinical examination under general anesthesia: improving parametrial assessment in cervical cancer patients[J/OL]. Cancers, 2021, 13(12): 2961 [2026-01-08]. https://pubmed.ncbi.nlm.nih.gov/34199156/. DOI: 10.3390/cancers13122961.
[9]
WOO S, ATUN R, WARD Z J, et al. Diagnostic performance of conventional and advanced imaging modalities for assessing newly diagnosed cervical cancer: systematic review and meta-analysis[J]. Eur Radiol, 2020, 30(10): 5560-5577. DOI: 10.1007/s00330-020-06909-3.
[10]
LIU X Y, MA X B, XU F. Diagnostic value of sagittal dynamic contrast-enhanced MRI combined with dual energy scanning CT in patients with stage Ⅱ cervical cancer with parauterine invasion[J]. J Clin Exp Med, 2023, 22(10): 1111-1114. DOI: 10.3969/j.issn.1671-4695.2023.10.028.
[11]
MA G J. Accuracy of transvaginal ultrasonography for staging of cervical cancer patients: a meta-analysis[J]. J Clin Ultrasound, 2025, 53(5): 1099-1110. DOI: 10.1002/jcu.23946.
[12]
WU M L, WU J W, HUANG L C, et al. Comparison of contrast-enhanced ultrasonography and magnetic resonance imaging in the evaluation of tumor size and local invasion of surgically treated cervical cancer[J]. Abdom Radiol, 2022, 47(8): 2928-2936. DOI: 10.1007/s00261-022-03558-6.
[13]
ZHANG J, JIN L F, JIA C, et al. Assessing local invasion in cervical cancer: the diagnostic performance of transrectal contrast-enhanced ultrasonography[J]. Br J Radiol, 2026, 99(1178): 400-408. DOI: 10.1093/bjr/tqaf283.
[14]
CIBULA D, KÖHLER C, JARKOVSKÝ J, et al. Magnetic resonance imaging and ultrasound examination in preoperative pelvic staging of early-stage cervical cancer: post-hoc analysis of SENTIX study[J]. Ultrasound Obstet Gynecol, 2025, 65(4): 495-502. DOI: 10.1002/uog.29205.
[15]
MA X, LI Q, WANG J L, et al. Comparison of elastography based on transvaginal ultrasound and MRI in assessing parametrial invasion of cervical cancer[J]. Clin Hemorheol Microcirc, 2017, 66(1): 27-35. DOI: 10.3233/CH-16235.
[16]
CHEN J, KITZING Y X, LO G. Systematic review-role of MRI in cervical cancer staging[J/OL]. Cancers, 2024, 16(11): 1983 [2026-01-08]. https://pubmed.ncbi.nlm.nih.gov/38893105/. DOI: 10.3390/cancers16111983.
[17]
BHATLA N, BEREK J S, CUELLO FREDES M, et al. Revised FIGO staging for carcinoma of the cervix uteri[J]. Int J Gynaecol Obstet, 2019, 145(1): 129-135. DOI: 10.1002/ijgo.12749.
[18]
VALENTINI A L, GUI B, MICCÒ M, et al. MRI anatomy of parametrial extension to better identify local pathways of disease spread in cervical cancer[J]. Diagn Interv Radiol, 2016, 22(4): 319-325. DOI: 10.5152/dir.2015.15282.
[19]
WOO S, MOON M H, CHO J Y, et al. Diagnostic performance of MRI for assessing parametrial invasion in cervical cancer: a head-to-head comparison between oblique and true axial T2-weighted images[J/OL]. Korean J Radiol, 2019, 20(3): 378 [2026-01-08]. https://pubmed.ncbi.nlm.nih.gov/30799568/. DOI: 10.3348/kjr.2018.0248.
[20]
SHAKUR A, LEE J Y J, FREEMAN S. An update on the role of MRI in treatment stratification of patients with cervical cancer[J/OL]. Cancers, 2023, 15(20): 5105 [2026-01-08]. https://pubmed.ncbi.nlm.nih.gov/37894476/. DOI: 10.3390/cancers15205105.
[21]
MAO L J, ZHANG X L, CHEN T T, et al. High-resolution reduced field-of-view diffusion-weighted magnetic resonance imaging in the diagnosis of cervical cancer[J]. Quant Imaging Med Surg, 2023, 13(6): 3464-3476. DOI: 10.21037/qims-22-579.
[22]
CHEN M Z, FENG C, WANG Q X, et al. Comparison of reduced field-of-view diffusion-weighted imaging (DWI) and conventional DWI techniques in the assessment of Cervical carcinoma at 3.0T: Image quality and FIGO staging[J/OL]. Eur J Radiol, 2021, 137: 109557 [2026-01-08]. https://pubmed.ncbi.nlm.nih.gov/33549900/. DOI: 10.1016/j.ejrad.2021.109557.
[23]
JIJO D N, SATISH CHODANKAR S, PARVEEN R, et al. Reduced field-of-view diffusion-weighted MRI: a systematic review of technical and clinical insights[J]. Egypt J Radiol Nucl Med, 2025, 56(1): 201 [2026-01-08]. https://link.springer.com/article/10.1186/s43055-025-01617-8. DOI: 10.1186/s43055-025-01617-8.
[24]
SONG Z Y, HU H, HUANG B F, et al. The value of T2WI sequence combined with reduced field of view diffusion weighted imaging in the diagnosis of cervical carcinoma parametrial invasion[J]. J Clin Radiol, 2021, 40(9): 1807-1811.
[25]
HUANG D H, QIN T, DU K, et al. Correlation between quantitative parameters of DCE-MRI and clinical stage, prognosis of cervical cancer[J]. J Hunan Norm Univ Med Sci, 2021, 18(4): 156-159. DOI: 10.3969/j.issn.1673-016X.2021.04.045.
[26]
NIU J Q, WANG J, LIU Y, et al. Diagnosis value of multimodal MRI quantitative analysis for parametrial infiltration in cervical cancer[J]. Chin J CT MRI, 2024, 22(5): 137-139. DOI: 10.3969/j.issn.1672-5131.2024.05.043.
[27]
LI X X, LIU B, CUI Y, et al. Intravoxel incoherent motion diffusion-weighted imaging and dynamic contrast-enhanced MRI for predicting parametrial invasion in cervical cancer[J]. Abdom Radiol, 2024, 49(9): 3232-3240. DOI: 10.1007/s00261-024-04339-z.
[28]
LIN T T, LI X X, LV W F, et al. Diagnostic value of combined intravoxel incoherent motion diffusion-weighted magnetic resonance imaging with diffusion tensor imaging in predicting parametrial infiltration in cervical cancer[J/OL]. Contrast Media Mol Imaging, 2021, 2021: 6651070 [2026-01-08]. https://pubmed.ncbi.nlm.nih.gov/34054375/. DOI: 10.1155/2021/6651070.
[29]
DI PAOLA V, PERILLO F, GUI B, et al. Detection of parametrial invasion in women with uterine cervical cancer using diffusion tensor imaging at 1.5T MRI[J]. Diagn Interv Imaging, 2022, 103(10): 472-478. DOI: 10.1016/j.diii.2022.05.005.
[30]
WU X F, LIANG X, WANG X C, et al. Differentiating high-grade glioma recurrence from pseudoprogression: Comparing diffusion kurtosis imaging and diffusion tensor imaging[J/OL]. Eur J Radiol, 2021, 135: 109445 [2026-01-08]. https://pubmed.ncbi.nlm.nih.gov/33341429/. DOI: 10.1016/j.ejrad.2020.109445.
[31]
WANG M D, PERUCHO J A U, VARDHANABHUTI V, et al. Radiomic features of T2-weighted imaging and diffusion kurtosis imaging in differentiating clinicopathological characteristics of cervical carcinoma[J]. Acad Radiol, 2022, 29(8): 1133-1140. DOI: 10.1016/j.acra.2021.08.018.
[32]
ZHANG Q, YU X D, OUYANG H, et al. Whole-tumor texture model based on diffusion kurtosis imaging for assessing cervical cancer: a preliminary study[J]. Eur Radiol, 2021, 31(8): 5576-5585. DOI: 10.1007/s00330-020-07612-z.
[33]
ZHENG X, SHEN F M, CHEN W J, et al. Integrated pretreatment diffusion kurtosis imaging and serum squamous cell carcinoma antigen levels: a biomarker strategy for early assessment of radiotherapy outcomes in cervical cancer[J]. Abdom Radiol (NY), 2024, 49(5): 1502-1511. DOI: 10.1007/s00261-024-04270-3.
[34]
CHEN X Y, HUANG Y S, et al. Enhancing parametrial invasion assessment in cervical squamous cell carcinoma: the collaborative impact of diffusion kurtosis imaging and T2-weighted imaging, exploring tumour core and 5-mm peritumoural tissue[J]. Br J Radiol, 2025, 98(1171): 1103-1111. DOI: 10.1093/bjr/tqaf100.
[35]
SHENG L J, YUAN E Y, YUAN F, et al. Amide proton transfer-weighted imaging of the abdomen: Current progress and future directions[J]. Magn Reson Imaging, 2024, 107: 88-99. DOI: 10.1016/j.mri.2024.01.006.
[36]
SONG Q L, TIAN S F, MA C J, et al. Amide proton transfer weighted imaging combined with dynamic contrast-enhanced MRI in predicting lymphovascular space invasion and deep stromal invasion of IB1-IIA1 cervical cancer[J/OL]. Front Oncol, 2022, 12: 916846 [2026-01-08]. https://pubmed.ncbi.nlm.nih.gov/36172148/. DOI: 10.3389/fonc.2022.916846.
[37]
LI S J, LIU J, ZHANG Z X, et al. Added-value of 3D amide proton transfer MRI in assessing prognostic factors of cervical cancer: a comparative study with multiple model diffusion-weighted imaging[J]. Quant Imaging Med Surg, 2023, 13(12): 8157-8172. DOI: 10.21037/qims-23-324.
[38]
DU L Z, YUAN Q H, ZHANG M D, et al. Using amide proton transfer-weighted magnetic resonance imaging (MRI) in peritumor tissue to predict parametrial infiltration of cervical cancer: a case-control study[J]. Quant Imaging Med Surg, 2024, 14(8): 5803-5813. DOI: 10.21037/qims-24-412.
[39]
YADAV D, O'DWYER E, AGEE M, et al. Unraveling the role of PET in cervical cancer: review of current applications and future horizons[J/OL]. J Imaging, 2025, 11(2): 63 [2026-01-08]. https://pubmed.ncbi.nlm.nih.gov/36172148/. DOI: 10.3390/jimaging11020063.
[40]
SINGARAM N K, HULIKAL N, VIJAYALAKSHMI DEVI B, et al. Utility of whole body 18F-FDG PET/CT in comparison to pelvic MRI in evaluation of local staging of early-stage carcinoma cervix[J/OL]. Cureus, 2022, 14(12): e32111 [2026-01-08]. https://pubmed.ncbi.nlm.nih.gov/36601156/. DOI: 10.7759/cureus.32111.
[41]
WANG T, SUN H Z, HAN F F, et al. Evaluation of parametrial infiltration in cervical cancer with voxel-based segmentation of integrated 18F-FDG PET/MRI images: a preliminary study[J]. Eur J Radiol, 2019, 118: 147-152. DOI: 10.1016/j.ejrad.2019.07.020.
[42]
CLAIRE T, MARC L J, PERRINE C, et al. MRI and ultrasound fusion imaging for cervical cancer[J]. Anticancer Res, 2017, 37(9): 5079-5085.
[43]
MORO F, GUI B, ARCIUOLO D, et al. Fusion imaging of ultrasound and MRI in the assessment of locally advanced cervical cancer: a prospective study[J]. Int J Gynecol Cancer, 2020, 30(4): 456-465. DOI: 10.1136/ijgc-2019-000902.
[44]
DAI X H, YE X X, REN J P, et al. Construction of the preoperative staging prediction model for cervical cancer based on deep learning and MRI: a retrospective study[J/OL]. Front Oncol, 2025, 15: 1557486 [2026-01-08]. https://pubmed.ncbi.nlm.nih.gov/40242247/. DOI: 10.3389/fonc.2025.1557486.
[45]
YANG C S, LI M, YI X, et al. Multiparametric MRI-based radiomics for preoperative prediction of parametrial invasion in early-stage cervical cancer[J/OL]. Front Oncol, 2025, 15: 1604749 [2026-01-08]. https://pubmed.ncbi.nlm.nih.gov/40823078/. DOI: 10.3389/fonc.2025.1604749.
[46]
HU Y, AI J. Development and validation of radiomics-based models for predicting the parametrial invasion in stage IB1 to IIA2 cervical cancer[J]. Int J Gen Med, 2024, 17: 3813-3824. DOI: 10.2147/IJGM.S478842.
[47]
SHANG F, TAN Z, GONG T, et al. Evaluation of parametrial infiltration in patients with IB-IIB cervical cancer by a radiomics model integrating features from tumoral and peritumoral regions in 18 F-fluorodeoxy glucose positron emission tomography/MR images[J/OL]. NMR Biomed, 2023: e4945 [2026-01-08]. https://pubmed.ncbi.nlm.nih.gov/37012600/. DOI: 10.1002/nbm.4945.
[48]
CUI Y M, LI Y, NA J, et al. Integration of radiomics, habitat imaging, and deep learning for MRI-based prediction of parametrial invasion in cervical cancer: a dual-center study[J/OL]. Magn Reson Imaging, 2026, 125: 110542 [2026-01-08]. https://pubmed.ncbi.nlm.nih.gov/41173217/. DOI: 10.1016/j.mri.2025.110542.
[49]
YANG K, PARK W, HUH S J, et al. Parametrial involvement on magnetic ResonanceImaging has No effect on the survival of early-StageCervical cancer patients[J]. Int J Gynecol Cancer, 2017, 27(3): 507-513. DOI: 10.1097/IGC.0000000000000909.

PREV CMR radiomics research progress in non-ischemic cardiomyopathy
NEXT Advances in the application of arterial spin labeling MRI in placental perfusion
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn